NSPR (InspireMD Inc) Return on Sales by Gross Profit

InspireMD, Inc. (NSPR) is implementing MicroNet technology, creating high switching costs for clinics. The company aims for global leadership in stroke protection through the CGuard system. The current launch of innovative stent systems is expanding its sales markets. The operational gross margin demonstrates production efficiency, and 12.60 reflects the latest metric value, allowing for an assessment of the business's technological superiority.
Comprehensive metric breakdowns and analytics for InspireMD, Inc. (NSPR)

Investors assess operational strength via the revenue share remaining after deducting direct production costs, as reflected in the base gross margin on GURU.Markets. For InspireMD, Inc. (NSPR), this production efficiency indicator is critical, as the slow adoption of carotid stents and high R&D expenses create a risk of declining profitability, calling into question the overall sustainability of the business model.